News about Global Pharma

TOOsonix Gets MDR CE Mark for its New Oncology and Dermatology Device

The certification allows TOOsonix to sell its flagship product, System ONE-M™, across the European Economic Area. Treatment of skin cancer and skin diseases can now be conducted in ways never before possible, providing more patient-friendly treatment than traditional procedures.

Global Pharma | 31/05/2024 | By Manvi |  299

Stevanato Group Inaugurates New Plant in Cisterna di Latina

Stevanato Group has recently launched its Cisterna di Latina plant.

Global Pharma | 31/05/2024 | By Aishwarya |  770

Sanofi Announces Complete Acquisition of Inhibrx

Sanofi has recently announced the complete acquisition of Inhibrx, Inc.

Global Pharma | 31/05/2024 | By Aishwarya |  280

Merck Signs MoU with KAIST to Boost Scientific Research

Merck has signed a non-binding Memorandum of Understanding (MoU) with the Korea Advanced Institute of Science and Technology (KAIST).

Global Pharma | 31/05/2024 | By Aishwarya |  386

PharmaLytica 2024 Commences Successfully in Hyderabad

Informa Markets India has announced the successful commencement of the 10th edition of PharmaLytica 2024 at HITEX, Hyderabad.

Global Pharma | 31/05/2024 | By Aishwarya |  1028

Nxera Pharma to Receive USD 4.6 Million from Centessa

Nxera Pharma has been expecting to receive USD 4.6 million in milestone payments from Centessa Pharmaceuticals under a license agreement regarding Nxera technology used to help design Centessa’s novel orexin receptor 2 (OX2R) agonist, ORX750.

Global Pharma | 30/05/2024 | By Aishwarya |  540

H.E.L Group Expands its Sales Newtowk with Addition of Two Specialist Distributors

H.E.L Group (H.E.L) has expanded its global sales network with the appointment of two distributors: Paralab and ProAnalytics.

Global Pharma | 30/05/2024 | By Aishwarya |  752

Merck Announces Acquisition of EyeBio

Merck has signed a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio.

Global Pharma | 30/05/2024 | By Aishwarya |  715

HanAll Biopharma and Turn Bio to Develop Novel Treatments for Eye and Ear Diseases

HanAll Biopharma Co., Ltd. has signed an exclusive licensing deal with Turn Biotechnologies, Inc., a pre-clinical stage biopharmaceutical company focused on cellular repair through epigenetic reprogramming.

Global Pharma | 29/05/2024 | By Aishwarya |  2640

Reddy Pharma Iberia and Theranica Launch Nerivio in Spain

Dr. Reddy's Laboratories Ltd. and its subsidiaries have introduced Nerivio in Spain through its step-down subsidiary, Reddy Pharma Iberia S.A.

Global Pharma | 29/05/2024 | By Aishwarya |  1120